New Research Peptides on the Horizon: A 2026 Pipeline Overview
Here is how fast metabolic research moves in 2026: one oral GLP-1 just crossed the finish line into approval while another washed out of development entirely, both inside the same year and a half. Keeping track of new research peptides in 2026 means watching a peptide pipeline that reshuffles almost every quarter. What follows is a map of what is advancing, grouped by the idea driving each cluster, plus a note on which mechanisms line up with peptides researchers can actually obtain. A caution up front: most of what is below is investigational and not approved, and a couple of the entries are not peptides at all.
| Category | Example compounds | Status | What it targets |
|---|---|---|---|
| Multi-receptor agonists | Retatrutide, survodutide, VK2735 | Phase 3 and Phase 2, investigational | Combinations of GIP, GLP-1, and glucagon receptors |
| Amylin combinations | CagriSema, cagrilintide | Under FDA review or investigational | Amylin receptors alongside GLP-1 |
| Oral small molecules (non-peptides) | Orforglipron, danuglipron | Orforglipron approved as Foundayo; danuglipron discontinued | GLP-1 receptor, taken as a tablet |
| Novel-mechanism compounds | GDF-15 modulators, oxyntomodulin and PYY analogs, apelin agonists | Early-stage research | GFRAL, Y2, APJ, and other non-incretin targets |
Multi-receptor agonists
This is the busiest lane. The pitch is simple - hit more than one gut-hormone receptor at once and the metabolic effects stack. retatrutide is the headline act, a triple agonist spanning GIP, GLP-1, and glucagon, now in Phase 3. Survodutide runs a leaner dual design on GLP-1 and glucagon, also in Phase 3, with a glucagon-forward tilt that has made it a MASH candidate. Viking Therapeutics' VK2735, a dual GLP-1 and GIP agonist, advanced on both injectable and oral fronts and drew extra attention after a rival oral program collapsed. All three remain investigational and unapproved. For two of them compared directly, the survodutide versus retatrutide piece does the work.
Amylin combinations
Amylin is a separate satiety hormone, and pairing an amylin analog with a GLP-1 agonist is the other combination strategy carrying real momentum. CagriSema - cagrilintide plus semaglutide, from Novo Nordisk - is the furthest along; the company filed for US approval and it sat under FDA review through 2026, still investigational until any decision lands. cagrilintide on its own is a long-acting amylin analog, also investigational. The logic and the research behind the pairing get unpacked in the CagriSema explainer.
Oral small molecules - the non-peptides
Not everything in this pipeline is a peptide, and this is the category where that distinction bites. Orforglipron is a non-peptide small-molecule GLP-1 agonist that graduated out of the pipeline in 2026, when US regulators approved it and Eli Lilly launched it as Foundayo - trademark to its owner, and an approved medicine rather than research material. Danuglipron, Pfizer's oral small-molecule GLP-1, went the other direction: the company discontinued its chronic weight-management program in 2025 after a safety signal. Both are assembled by chemical synthesis, not from amino acids, so neither is a peptide and neither is sold as a research peptide. They belong here because they show how the oral small-molecule route can end in a launch or a dead end.
Novel-mechanism compounds
Beyond the incretin receptors, earlier-stage research is probing several fresh targets. GDF-15 pathway modulators act through the GFRAL receptor in the brainstem to influence appetite. Oxyntomodulin analogs - pemvidutide is one - revive a natural gut hormone that hits GLP-1 and glucagon at once. PYY analogs aim at the Y2 receptor to reinforce satiety through a route separate from GLP-1. Apelin agonists target the APJ receptor and sit where metabolic and cardiovascular research overlap. Will any of them reach a clinic? Too early to say - but this is the tier where the next round of surprises usually starts.
Which researcher-available peptides map to these themes
Much of the pipeline is locked inside company programs, yet several of the underlying mechanisms are represented by peptides used in research right now. semaglutide is the GLP-1 backbone that the amylin combinations and the multi-agonist designs build around. Tirzepatide, a dual GIP and GLP-1 agonist, is effectively the template every triple agonist extends. Retatrutide carries the triple-agonist idea itself. Cagrilintide stands in for the amylin arm of the CagriSema story. And MOTS-c sits in a lane of its own - a mitochondrial-derived peptide studied for metabolism rather than incretin signaling, a reminder that metabolic research runs wider than the GLP-1 headline. For the fuller catalog of what is studied here, see the metabolic research overview, and for how the flagship agonists stack up, the three-way comparison. The research-grade compounds themselves are in the catalog. Every investigational name above is exactly that - investigational, not approved, and studied for research rather than sold as a treatment.
Research use only. This article is educational and is not medical, legal, or financial advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.